Loading
Spevatamig is an experimental bispecific antibody from Phanes Therapeutics in phase 2 trials for gastric & gastro-oesophageal junction cancer, pancreatic ductal adenocarcinoma and biliary tract cancer, aimed at Claudin 18.2 and CD47.
Spevatamig (PT886) is a bispecific antibody developed by Phanes Therapeutics. Its targets are Claudin 18.2 and CD47. ClinicalTrials.gov describes the intervention as: Spevatamig (PT886) monotherapy, a novel bispecific antibody that targets Claudin 18.2 and CD47. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in gastric & gastro-oesophageal junction cancer, pancreatic ductal adenocarcinoma and biliary tract cancer. The largest, NCT05482893, plans to enrol 258 participants with primary completion expected 2027-12. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
Bispecific antibody directed at Claudin 18.2 and CD47, as stated in the ClinicalTrials.gov intervention record; the detailed mechanism is not stated. Connects to Claudin 18.2 and CD47.
1.One arm of Spevatamig binds Claudin 18.2 on the cancer cell.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Spevatamig" OR ABSTRACT:"Spevatamig" OR TITLE:"PT886" OR ABSTRACT:"PT886" OR TITLE:"Spevatamig PT886" OR ABSTRACT:"Spevatamig PT886") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Spevatamig, not a curated reading list.
Shares Claudin 18.2, Biliary tract cancer (cholangiocarcinoma), Gastric & gastro-oesophageal junction cancer, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Claudin 18.2, Biliary tract cancer (cholangiocarcinoma), Gastric & gastro-oesophageal junction cancer, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Phanes Therapeutics, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Phanes Therapeutics, CD47 and the tag pipeline.
Shares Biliary tract cancer (cholangiocarcinoma), Gastric & gastro-oesophageal junction cancer, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Biliary tract cancer (cholangiocarcinoma), Gastric & gastro-oesophageal junction cancer, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Claudin 18.2, Gastric & gastro-oesophageal junction cancer, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Biliary tract cancer (cholangiocarcinoma), Pancreatic ductal adenocarcinoma and the tag pipeline.